These studies provide experimental evidence showing the possible mechanisms by which CCH can contribute to cognitive impairment and AD probably through reduction of protein O-GlcNAcylation, hyperphosphorylation of tau, dysregulated synaptic plasticity and neural degeneration in the brain. The gene discussed is MAPT; the disease is Alzheimer disease.